California Institute of Technology

University of California

Lili Yang

David Baltimore

Pin Wang

Antoni Ribas

James Economou

Drake J Smith

Kenneth Yu

Xin Luo

Luk Van Parijs

Disclosed herein are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof.

Engineered invariant natural killer T (iNKT) cells and methods of making and using thereof

Disclosed are invariant natural killer T (iNKT) cells engineered using hematopoietic stem and progenitor cells (HSPCs) and methods of making and using thereof. Specifically, the engineered cells iNKT are genetically modified to contain at least one exogenous invariant natural killer T cell receptor (iNKT TCR) nucleic acid molecule. Further disclosed are iNKT TCR nucleotide sequences and codon optimized sequences for expression.

Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.

Packaging cell for making a pseudotyped lentivirus

Methods of delivering a pseudotyped lentivirus

Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic molecule is also present on the envelope and facilitates delivery of the polynucleotide across the membrane and into the cytosol of the target cell. The methods and related compositions can be used for treating patients having suffering from a wide range of conditions, including infection, such as HIV; cancers, such as non-Hodgkin's lymphoma and breast cancer; and hematological disorders, such as severe combined immunodeficiency.

Method of targeting gene delivery using viral vectors

Recombinant retrovirus pseudotyped with E2 alphavirus glycoprotein

Some embodiments herein provide compositions and methods for expressing secreted and cell-surface-bound polypeptides in a single cell. In some embodiments, secreted and cell-surface polypeptide are produced from a single polynucleotide. The polynucleotide can comprise a sequence (or sequence encoding a polypeptide) that mediates separation of a membrane anchor from the polypeptide. In some embodiments, a desired ratio of secreted to surface-bound polypeptide is obtained by selecting a sequence that mediates a desired level of separation of the membrane anchor from the polypeptide.

Expression of secreted and cell-surface polypeptides

Method of stimulating an immune response using a pseudotyped lentivirus

Recombinant retrovirus pseudotyped with a E2 alphavirus glycoprotein

Method of targeted gene delivery using viral vectors

T-cell receptors that recognize MART-1 antigen are provided. The TCRs can be used, for example, to treat patients suffering from melanoma.

MART-1 T cell receptors

Recombiant lentivirus comprising an E2 alphavirus glycoprotein that binds to DC-SIGN

Targeted gene delivery for dendritic cell vaccination

Targeted gene delivery to dendritic cells

The present disclosure relates to systems, methods and compositions for the generation of antibody-producing B cells in vitro. Some embodiments are related to an in vitro system for generating antibody-producing B cells from hematopoietic stem/progenitor cells (HSPCs).

Growing community of inventors

Arcadia, CA, United States of America

Lili Yang